Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
+3.15 (1.09%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 289.29 - 292.86
52 week 254.00 - 480.18
Open 290.00
Vol / Avg. 1.14M/2.85M
Mkt cap 64.45B
P/E 19.09
Div/yield     -
EPS 15.31
Shares 222.90M
Beta 0.87
Inst. own 91%
Jan 27, 2016
Q4 2015 Biogen Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 3, 2015
Biogen Inc Investor R&D Day
Oct 21, 2015
Q3 2015 Biogen Inc Earnings Release
Oct 21, 2015
Q3 2015 Biogen Inc Earnings Call
Sep 18, 2015
Biogen Inc at Bank of America Merrill Lynch Global Healthcare Conference
Sep 16, 2015
Biogen Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 36.95% 30.47%
Operating margin 49.38% 40.94%
EBITD margin - 47.46%
Return on average assets 21.96% 22.59%
Return on average equity 33.47% 30.21%
Employees 7,550 -
CDP Score - 81 C


225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia


Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company's marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
George A. Scangos Ph.D. Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 56
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 58
Bio & Compensation  - Reuters
John G. Cox Executive Vice President - Global Commercial Operations
Age: 52
Bio & Compensation  - Reuters
Steven H. Holtzman Executive Vice President - Corporate Development
Age: 60
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology and Business Solutions
Age: 52
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Executive Vice President - Research and Development
Age: 57
Bio & Compensation  - Reuters
Matt Griffiths Senior Vice President, Chief Information Officer
Bio & Compensation  - Reuters